Your donation will make a difference:
Cystic Fibrosis Trust

UKCFC 2017: day one

'The role of CFTR in keeping lungs healthy'

Wednesday 6 September 2017

Buy tickets for day one

9.00 Registration and networking
10.00 Welcome and conference introduction

David Ramsden, Chief Executive of the Cystic Fibrosis Trust, and George Jenkins OBE, Chairman of the Cystic Fibrosis Trust.

Session One

10.10 Understanding how CFTR keeps lungs healthy and what to do about it when it doesn't work

Chair: David Sheppard, Professor of Physiology

University of Bristol

Introductory chair scene setting (five minutes) followed by four researcher presentations.

10.15 The importance of the Air-Surface Liquid (ASL) interface - volume and pH

Robert Tarran, Associate Professor of Cell Biology and Physiology

University of North Carolina, USA.

  • Why the ASL is important.
  • The role of CFTR in controlling ASL - volume and pH.
  • Consequences of CFTR dysfunction.
10.40 Visualising the cilia

Dr Pietro Cicuta, Head of Biological and Soft Systems, Cavendish Laboratory, University of Cambridge 

  • Advanced physics to visualise ciliary beats.
11.00 Can we target other channels?

Dr Michael Gray, Cellular Physiology

University of Newcastle.

  • Other ion channels also contribute to the health of the surface epithelium.
  • Understanding these channels offers new opportunities to find alternative therapies for CF.

11.15 Yes we can! 'Hot off the press'

Dr Henry Danahay, Head of Biology Enterprise Therapeutics (tbc)

  • Targeting the other channels involved in ASL.
  • Novel technology using bronchospheres to screen for compounds that influence ASL.
11.30 Coffee and networking (exhibition area)

Session Two

11.45 Mucus

Chair: David Thornton, Professor of Biochemistry

University of Manchester.

Introductory chair scene setting (five minutes) followed by two research presentations.

11.50 Sticky mucus: how does ion channel dysfunction affect mucus in the lungs?

Anna Ermund, Medical Biochemistry and Cell Biology

University of Gothenburg

  • Sticky mucus results in ion-slowed mucociliary clearance.
  • How does CFTR dysfunction result in sticky mucus?
  • How can an understanding of these processes help identify new ways of treating the lungs?
12.20 'Hot off the press'

Astrid Hilde Myrset, Director of Clinical and Pre-Clinical Research


  • OligoG: A novel approach to treating mucus dysfunction.
  • Phase 2b results and plans for the future.
12.30 Conference lunch (exhibition area)

Meet the sponsors, networking and poster viewing (exhibition area)

13.00 Sponsor lunchtime symposium: 'Beyond the lung - will Cinderella go to the ball?'

Organised by Vertex

Professor Alan Smyth, School of Medicine, University of Nottingham and Nottingham Children's Hospital

Session Three

13.55 Pulmonary infection and inflammation

Chair: Andres Floto, Professor of Respiratory Biology, University of Cambridge (TBC)

Introductory chair scene setting (five minutes) followed by research presentations.

14.00 Pulmonary infection by Pseudomonas aeriginosa. The case for new antimicrobials

Jane Davies, Professor in Paediatric Respirology

Imperial College London and Royal Brompton Hospital

  • Understanding PsA infection in the CF lung.
  • Developing better understanding of the lung milieu that leads to chronic infection with PsA.
  • The difficulties in finding novel antibiotics that are effective in the CF lung.
14.30 Why is it so hard to find new antibiotics?

Will Hall, previously Senior Policy Adviser on the Review into Antimicrobial Resistance

  • Report on Antimicrobial Resistance: implications 
15.00 A novel therapeutic approach to resolve inflammation in CF

Barbara White, MD Chief Medical Officer

Corbus Pharmaceuticals, Inc

  • Excessive and ineffective inflammatory response is a feature of CF and likely leads to progressive decline in lung function.
  • Importance of the resolution phase of innate immune responses in restoring homeostasis.
  • Results for the Phase 2 study in CF with the cannabinoid receptor type 2 agonist, anabasum (aka JBT-101)
15.20 What happens if we correct CFTR? Long term follow up data on use of Ivacaftor.

Stuart Elborn, Professor of Respiratory Medicine

Imperial College London and Royal Brompton Hospital

  • What can we learn from the long-term studies (five years) on Ivacaftor in people with G551D?
  • How much lung function is reversible?
15.50 Closing comments and close of conference day one
16.45 'CF's Got Talent!' (conference theatre)

Presentations and award ceremony for young CF researchers and people with CF and their families (full online streaming and interaction with CF community)

Chair: Roger Black, Olympian and presenter 

Summer Student poster session - judging panel (exhibition area)

19.00 Drinks reception and networking opportunity (atrium)
19.30 Conferences and fundraising gala dinner (exhibition area)

Guest speaker (tbc)

Prizes awarded for CF's Got Talent and Summer Students

Buy tickets for the conference dinner

22.00 Close of day one

This meeting is supported by companies, including pharmaceutical companies, who will be exhibiting at the event and pharmaceutical staff will be present throughout the meeting.

Research we're funding

The Trust is committed to funding and supporting cutting-edge research to find new and better treatments for cystic fibrosis. Take a look at some of that work and the progress that is being made.

Discover more

What is cystic fibrosis?

Find out more about cystic fibrosis, its diagnosis and how it is treated, as well as useful links to our publications and other organisations who can help.

Read on

More information

If you would like to find out more about any of our campaigns, publications or anything else, get in touch and we'll be happy to help.

Get in touch